Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867139 · ClinicalTrials.gov registry record · Phase 1
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
A Phase 1 study of Influenza, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 2
- Study locations
NCT00867139: Completed Phase 1 study of Influenza, sponsored by Fred Hutchinson Cancer Center.
NCT00867139 is a Phase 1 study of Influenza that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 7 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867139, a Phase 1 study of Influenza, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
Primary Outcome
Abnormal lab data or newly appeared symptoms \& signs were considered as AEs. Examined lab data: Blood cell count (WBC, differential count, Red Blood Cell (RBC), Hemoglobin, Hematocrit, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin Concentration (MCHC), platelets), Chemistry (Cl, bicarbonate (HCO3), K, Na), Renal function test (BUN, Creatinine, Creatinine clearance), Liver function test (AST, Alanine aminotransferase(ALT), T.Bil, gamma-glutamyltransferase)
Conditions Studied
Interventions
- DRUG TCAD
- DRUG Zanamivir or Oseltamivir
- OTHER Open label treatment with TCAD
Study Locations (2)
Washington
- Seattle Children's - Seattle
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00867139 record still lists
NCT00867139 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which TCAD is the first listed.
NCT00867139 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00867139 about?
NCT00867139 is a clinical study titled "TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients". The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
What is the current status of trial NCT00867139?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-03. Estimated completion is 2010-01.
What conditions does trial NCT00867139 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00867139?
The interventions under investigation include: TCAD (DRUG), Zanamivir or Oseltamivir (DRUG), Open label treatment with TCAD (OTHER).
Who is sponsoring clinical trial NCT00867139?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00867139 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00867139's enrollment target sits among peer trials
7 156th of 156 higher than 1 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia